European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 327-332 , October 2003

Brain neurosteroid changes after paroxetine administration in mice

  • Allon Nechmad

      Affiliations

    • Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel
    • Shalvata Mental Health, Hod-Hasharon, Israel
    • ,
  • Rachel Maayan

      Affiliations

    • Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel
    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Baruch Spivak

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Research Unit, Ness Ziona Mental Health Center, Ness Ziona, Israel
    • ,
  • Edward Ramadan

      Affiliations

    • Department of Surgery A, Rabin Medical Center, Campus Golda, Petach-Tikva, Israel
    • ,
  • Michael Poyurovsky

      Affiliations

    • Research Unit, Tirat Carmel Mental Health Center and Faculty of Medicine, Institute of Technology, Technion Haifa, Israel
    • ,
  • Abraham Weizman

      Affiliations

    • Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel
    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Research Unit, Geha Psychiatric Hospital, Beilinson Campus, Petah Tikva, Israel
    • Corresponding Author InformationCorresponding author. Research Unit, Geha Psychiatric Hospital, P.O.B. 102, Petach-Tikva 49100, Israel. Tel.: +972-3-925-8290; fax: +972-3-924-1041.

Received 13 August 2002 ,Accepted 7 January 2003.

References 

  1. Altar CA. Neurotrophins and depression. Trends Pharmacol. Sci. 1999;2:59–61
  2. Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 1998;23:963–987
  3. Bernardi F, Lanzone A, Cento RM, Spada RS, Pezzani I, Genazzani AD, et al. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer’s disease and vascular dementia. Eur. J. Endocrinol. 2000;142:466–471
  4. Bicikova M, Dibbelt L, Hill M, Hampl R, Starka L. Allopregnanolone in women with premenstrual syndrome. Horm. Metab. Res. 1998;30:227–230
  5. Budziszewska B, Siwanowicz J, Leskiewicz M, Jaworska-Feil L, Lason W. Protective effects of neurosteroids against NMDA-induced seizures and lethality in mice. Eur. Neuropsychopharmacol. 1998;8:7–12
  6. Dong E, Matsumoto K, Uzunova VV, Sugaya II, Takahata H, Nomura H, et al. Brain 5-alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. USA. 2001;85:2849–2854
  7. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA. 1999;96:13512–13517
  8. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability?. Biol. Psychiatry. 1998;44:865–873
  9. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 1997;74:299–316
  10. Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 1992;38:379–395
  11. Melcangi RC, Cavarretta I, Magnaghi V, Ballabio M, Martini L, Motta M. Crosstalk between normal and tumoral brain cells. Endocrine. 1998;8:65–71
  12. Mensah-Nyagan AG, Do-Rego D-L, Beaujeau D, Van L-T, Pelletier G, Vaudy H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Parmacol. Rev. 1999;51:63–82
  13. Pinna G, Uzunoca V, Matsumoto K, Puia G, Mienville JM, Costa E, et al. A brain allopregnanolone regulates the potency of the GABA(A) receptor agonist muscimol. Neuropharmacology. 2000;39:440–448
  14. Purdy RH, Morrow AL, Moore PH, Paul SM. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA. 1991;88:4553–4557
  15. Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 1998;155:910–913
  16. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1999;56:1043–1047
  17. Schatzberg AF. New indications for antidepressants. J. Clin. Psychiatry. 2000;61(Suppl. 11):9–17
  18. Spivak B, Maayan R, Mester R, Gil-ad I, Shtaif B, Kotler M, et al. Elevated circulatory level of GABAA-antagonistic neurosteroids in patients with a combat-related post-traumatic stress disorder. Psychol. Med. 2000;20:1227–1231
  19. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998;51:215–235
  20. Stewart CA, Reid IC. Repeated ECS and fluoxetine administration have equivalent effect on hippocampal synaptic plasticity. Psychopharmacology (Berl.). 2000;148:217–223
  21. Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA. 1996;93:12599–12604
  22. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA. 1998;95:3239–3244
  23. Wieland S, Belluzzi J, Hawkinson JE, Hogenkamp D, Upasani R, Stein L, et al. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology (Berl.). 1997;134:46–54

PII: S0924-977X(03)00015-4

doi: 10.1016/S0924-977X(03)00015-4

European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 327-332 , October 2003

Article Tools

* Image Usage & Resolution